GT Biopharma, Inc. (GTBP) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. GT Biopharma is a clinical-stage biopharmaceutical company developing immune-oncology products based on its proprietary TriKE® and Dual Targeting TriKE® platforms. The company operates as a single segment and became fully remote effective July 1, 2024. As of May 13, 2025, there were 2,586,397 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(776,000) | $(2,266,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.33) | $(1.64) |
| Operating Expenses | $1,932,000 | $3,091,000 |
| Cash and Cash Equivalents | $2,365,000 | $3,951,000 (Dec 31, 2024) |
| Working Capital Deficit | $(980,000) | $(1,670,000) (Dec 31, 2024) |
| Net Cash Used in Operating Activities | $(2,202,000) | $(4,163,000) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $1.49 million (66%) compared to Q1 2024, driven by significant reductions in legal fees, consulting fees, and salaries.
- Operating Expenses: Total operating expenses declined 37% to $1.93 million. Selling, general, and administrative (SG&A) expenses dropped 62% to $833,000, while Research and Development (R&D) expenses increased 41% to $1.099 million due to scientific research costs for product candidates.
- Non-Cash Gains: The company recorded a $998,000 gain on the settlement of a vendor payable (legal fees) and a $126,000 gain from the change in fair value of warrant liability.
- Liquidity: Cash balances decreased by approximately $1.59 million during the quarter. However, the working capital deficit improved by $690,000 compared to the prior year-end.
Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern. Management believes existing cash resources are insufficient to fund operations for one year without additional financing.
- NASDAQ Compliance: The company received a notification in November 2024 regarding non-compliance with the Minimum Stockholders' Equity Requirement ($2.5 million). A plan to regain compliance via securities offerings was submitted but not yet accepted by the Staff. Subsequent financing in May 2025 is expected to restore pro forma equity to at least $2.5 million.
- Legal Proceedings:
- Ohri Matter: Arbitration against former CFO Manu Ohri regarding breach of fiduciary duties; final hearing scheduled for June 2025.
- TWF Global/Z-One Matter: Ongoing dispute regarding convertible promissory notes and share registration; a new summons was filed by Z-One in February 2025.
- Subsequent Events:
- On May 12, 2025, the company entered a private placement for Series L Convertible Preferred Stock and warrants with an aggregate purchase price of $5.45 million.
- On May 14, 2025, the company entered a committed equity facility allowing the sale of up to $20 million of common stock.
Investor Verification Checklist
- Financing Execution: Verify the closing of the May 2025 private placement and the acceptance of the NASDAQ compliance plan to assess delisting risk.
- Cash Runway: Confirm the actual cash burn rate post-Q1 and the sufficiency of the $5.45 million raised in May to fund the GTB-3650 clinical trial.
- Legal Accruals: Review the adequacy of accruals for the Ohri arbitration and Z-One litigation, as outcomes remain uncertain.
- Related Party Transactions: Monitor the settlement of accounts payable to Cytovance (a related party) via prefunded warrants and the impact on dilution.
- Clinical Progress: Track enrollment and data readouts for the GTB-3650 Phase 1 trial, which began enrollment in January 2025.